Clinical trials: Systemic Sclerosis Pulmonary
Interstitial Lung Disease Due to Systemic Disease (Disorder)
Use of Selective JAK Inhibitor in ILD and Skin Tightness of Systemic Sclerosis Versus MMF
Systemic sclerosis (SSc) is a systemic autoimmune disease with heterogeneous clinical presentation and prognosis. JAK inhibitors reduced cutaneous and pulmonary fibrosis in mice models of SSc.
- Trial name
- upadacetinib (NCT06758947)
- Testing
- Upadacitinib 15 MG, Cellcept Oral Product
- Where
- Egypt
- Volunteers
- 60 people
- Sponsor
- Assiut University
Systemic Sclerosis, Diffuse Sclerosis Systemic
Autologous Stem Cell Transplantation in Patients With Systemic Sclerosis
The purpose of this study is to determine whether a regimen of high-dose immunoablative therapy will demonstrate safety that is consistent or improved with other published regimens in SSc patients, while maintaining a treatment…
- Conditions
- Systemic Sclerosis, Diffuse Sclerosis Systemic, Interstitial Lung Disease, Pulmonary Hypertension
- Trial name
- SSc (NCT03630211)
- Testing
- Cyclophosphamide, Mesna, Rituximab
- Where
- 3 sites in United States
- Volunteers
- 8 people
- Sponsor
- Paul Szabolcs
Interstitial Lung Disease, Systemic Sclerosis
The Role of Gastroesophageal Reflux in Scleroderma Pulmonary Fibrosis
Scarring of the lungs is common in patients with scleroderma and is one of the main causes of death. Patients with scleroderma very frequently have problems with their gullet (esophagus), the food pipe that leads into the…
- Conditions
- Interstitial Lung Disease, Systemic Sclerosis, Gastroesophageal Reflux
- Trial name
- NCT02136394
- Testing
- Gastro-esophageal reflux
- Where
- 2 sites in United Kingdom
- Volunteers
- 100 people
- Sponsor
- Royal Brompton & Harefield NHS Foundation Trust
Systemic Sclerosis
Nitric Oxide Lung Diffusing Capacity in Systemic Sclerosis
To date, two devices to measure nitric oxide lung diffusing capacity (DLNO) are commercially available in Europe. Previous research has shown systematic between-device differences in lung diffusing capacity outcomes in healthy…
- Trial name
- NCT05505617
- Testing
- Single-breath nitric oxide lung diffusing capacity measurements according to type of device in random order.
- Where
- Switzerland
- Volunteers
- 9 people
- Sponsor
- Holger Dressel
Associated Pulmonary Arterial Hypertension
To Compare the Efficacy of Combination Therapy vs Monotherapy for Pulmonary Arterial Hypertension in Systemic Sclerosis
The study will be carried out on 50 consecutive consenting patients of systemic sclerosis with PAH recruited from outpatient department of internal medicine and rheumatology clinic of PGIMER, Chandigarh, India It is a single…
- Trial name
- BosSilSS (NCT03053739)
- Testing
- Sildenafil 20mg and Bosentan 62.5mg
- Where
- India
- Volunteers
- 50 people
- Sponsor
- Post Graduate Institute of Medical Education and Research, Chandigarh
Systemic Sclerosis, Interstitial Lung Disease
Study of the Efficacy of Nintedanib+Tocilizumab in Patients With Systemic Sclerosis and Interstitial Lung Disease
The study includes adult patients with systemic sclerosis (SSc) with interstitial lung disease (ILD) to evaluate the efficacy and safety of nintedanib plus tocilizumab combination therapy compared to standard therapy…
- Trial name
- NINTOC-TU (NCT06297096)
- Testing
- Tocilizumab, Nintedanib, Standard therapy
- Where
- Poland
- Volunteers
- 86 people
- Sponsor
- National Institute of Geriatrics, Rheumatology and Rehabilitation, Poland
Pulmonary Fibrosis Secondary to Systemic Sclerosis
QAX576 in Patients With Pulmonary Fibrosis Secondary to Systemic Sclerosis
This study will evaluate the safety, tolerability, and mechanism of action of multiple doses of QAX576 in patients with pulmonary fibrosis secondary to systemic sclerosis
- Trial name
- NCT00581997
- Testing
- QAX576
- Volunteers
- 8 people
- Sponsor
- Novartis Pharmaceuticals
Idiopathic Pulmonary Arterial Hypertension, Heritable Pulmonary Arterial Hypertension
Hormonal, Metabolic, and Signaling Interactions in PAH
Our hypothesis is that optimal treatment of the dysfunctional metabolic pathways which underlie PAH will improve pulmonary vascular function and consequences of the disease.
- Conditions
- Idiopathic Pulmonary Arterial Hypertension, Heritable Pulmonary Arterial Hypertension, Scleroderma Associated Pulmonary Arterial Hypertension, Appetite Suppressant Associate PAH
- Trial name
- NCT01884051
- Where
- United States
- Volunteers
- 1,899 people, healthy volunteers welcome
- Sponsor
- Vanderbilt University Medical Center
Systemic Sclerosis (SSc), Pulmonary Arterial Hypertension (PAH)
Home-Based Clinical Management of Cardiac Complications in Systemic Sclerosis
The goal of this observational pilot trial is to evaluate the feasibility of home monitoring for patients with systemic sclerosis-associated pulmonary arterial hypertension (SSc-PAH).
- Conditions
- Systemic Sclerosis (SSc), Pulmonary Arterial Hypertension (PAH), Home Monitoring Follow-up
- Trial name
- Nor-SScCare (NCT06865118)
- Where
- Norway
- Volunteers
- 20 people
- Sponsor
- Oslo University Hospital
Interstitial Lung Disease Due to Systemic Disease, Scleroderma
Platform Clinical Study for Conquering Scleroderma
The goal of this clinical trial is to test efficacy of different investigational products (IPs) compared with placebo on the change from baseline to the end of the treatment period at Week 52 in lung capacity in participants with…
- Trial name
- CONQUEST (NCT06195072)
- Testing
- Amlitelimab, BI 1015550 (Nerandomilast)
- Where
- 34 sites in United States
- Volunteers
- 400 people
- Sponsor
- Scleroderma Research Foundation, Inc.
Pulmonary Arterial Hypertension, Systemic Sclerosis
Volatile Organic Compounds (VOCs) as a Biomarker in Immune-mediated Pulmonary Arterial Hypertension (PAH)
Aim: to investigate the role of inflammation and auto-immunity in pulmonary arterial hypertension by using the profile of volatile organic compounds.
- Conditions
- Pulmonary Arterial Hypertension, Systemic Sclerosis, Systemic Lupus
- Trial name
- VOC-PAH (NCT03819777)
- Where
- Netherlands
- Volunteers
- 150 people
- Sponsor
- Maastricht University Medical Center
Chronic Obstructive Pulmonary Disease (COPD), Smoking
Collection of Airway, Blood and/or Urine Specimens From Subjects for Research Studies
The purpose of this study is to obtain biologic materials from the blood, airways and/or urine of normal individuals and individuals with lung disease.
- Conditions
- Chronic Obstructive Pulmonary Disease (COPD), Smoking, Smoking Cessation, Idiopathic Pulmonary Fibrosis (IPF)
- Trial name
- NCT01776398
- Where
- United States
- Volunteers
- 2,000 people, healthy volunteers welcome
- Sponsor
- Weill Medical College of Cornell University
Systemic Sclerosis, Pulmonary Hypertension
Development and Prevention of Pulmonary Hypertension in Systemic Sclerosis
Systemic sclerosis (SSc) is an orphan, multiorgan disease affecting the connective tissue of the skin and several internal organs.
- Trial name
- NCT01840748
- Where
- 11 sites in France, Germany and 4 more
- Volunteers
- 960 people
- Sponsor
- University of Paris 5 - Rene Descartes
Systemic Sclerosis, Scleroderma
Multi-center, Web Based Observational Study of Pulmonary Hypertension in Scleroderma Patients
The purpose of this study is to determine the timeline of progression from pre-pulmonary hypertension to diagnosable pulmonary hypertension based on right heart catheterization.
- Conditions
- Systemic Sclerosis, Scleroderma, Pulmonary Hypertension, Pulmonary Arterial Hypertension
- Trial name
- NCT00377949
- Where
- 25 sites in United States
- Volunteers
- 602 people
- Sponsor
- Georgetown University
Lung Diseases, Interstitial, Systemic Sclerosis
Comparing and Combining Bortezomib and Mycophenolate in SSc Pulmonary Fibrosis
The purpose of this study is to look at whether bortezomib, mycophenolate or the combination of both is better to treat scarring of the lung caused by Systemic Sclerosis.
- Conditions
- Lung Diseases, Interstitial, Systemic Sclerosis, Scleroderma
- Trial name
- NCT02370693
- Testing
- Bortezomib, Mycophenolate mofetil
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Northwestern University
Diffuse Cutaneous Systemic Sclerosis, Interstitial Lung Disease
Phase 2 Safety and Efficacy Study of Tulisokibart (MK-7240/PRA023) in Subjects With Systemic Sclerosis Associated With Interstitial Lung Disease (SSc-ILD) (MK-7240-007)
The purpose of this study is to assess the safety and efficacy of tulisokibart in participants with SSc-ILD.
- Trial name
- ATHENA-SSc-ILD (NCT05270668)
- Testing
- Tulisokibart, Companion diagnostic ( CDx)
- Where
- 95 sites in United States, Argentina and 18 more
- Volunteers
- 154 people
- Sponsor
- Prometheus Biosciences, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Scleroderma, Pulmonary Artery Hypertension
Cardiac Assessment by PV Loop in IPAH and Scleroderma PAH
This observational study is being done to understand why people with scleroderma can develop pulmonary arterial hypertension (high blood pressure in the lungs, abbreviated PAH) and a weak heart muscle (heart failure).
- Trial name
- CALIPSO (NCT04610788)
- Where
- United States
- Volunteers
- 43 people
- Sponsor
- Johns Hopkins University
All Diagnosed Health Conditions, ADD/ADHD
At-Home Research Study for Patients With Autoimmune, Inflammatory, Genetic, Hematological, Infectious, Neurological, CNS, Oncological, Respiratory, Metabolic Conditions
We are the missing link in clinical trials, connecting patients and researchers seamlessly and conveniently using a mobile health platform to advance medical research.
- Conditions
- All Diagnosed Health Conditions, ADD/ADHD, Alopecia Areata, Ankylosing Spondylitis
- Trial name
- NCT01931644
- Where
- United States
- Volunteers
- 17,667 people, healthy volunteers welcome
- Sponsor
- Sanguine Biosciences
Systemic Scleroderma
Evaluation of the Serum Soluble Fractalkine as a Biomarker of Pulmonary Fibrosis in Systemic Sclerosis
Systemic Scleroderma (SCS) is an autoimmune disease characterized by vascular involvement, a dysimmune condition, cutaneous and visceral fibrosis.
- Trial name
- SCLEROLUNG (NCT03508375)
- Testing
- blood samples
- Where
- France
- Volunteers
- 75 people
- Sponsor
- Assistance Publique Hopitaux De Marseille
Pirfenidone, Connective Tissue Diseases
Immunosuppressant Combined With Pirfenidone in CTD-ILD
A prospective cohort study was used to observe the efficacy and safety of different immunosuppressive agents with/wo pirfenidone on CTD-ILD patients in Qilu Hospital of Shandong University for 36 months.The main research…
- Conditions
- Pirfenidone, Connective Tissue Diseases, Interstitial Lung Disease
- Trial name
- NCT04928586
- Testing
- Pirfenidone, DMARDs
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Qilu Hospital of Shandong University